Aktienanalyse zu Balchem Corporation (BCPC)BCPCBalchem Corporation

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance, with a current price of $170.73 and a forward P/E ratio of 29.33, indicating reasonable valuation relative to growth expectations. The company reported a 11.2% year-over-year revenue growth in Q2 2026, reaching $284 million, which exceeded expectations. However, the main risk is the high RSI of 72.67, indicating that the stock may be overbought in the short term.